Format

Send to

Choose Destination
Semin Cell Dev Biol. 2010 Dec;21(9):951-60. doi: 10.1016/j.semcdb.2010.08.009. Epub 2010 Sep 9.

EGFR signaling in breast cancer: bad to the bone.

Author information

1
Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN 47405, USA. jgfoley@indiana.edu

Abstract

The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor tyrosine kinases. This family includes EGFR/ErbB1/HER1, ErbB2/HER2/Neu ErbB3/HER3, and ErbB4/HER4. For many years it was believed that EGFR plays a minor role in the development and progression of breast malignancies. However, recent findings have led investigators to revisit these beliefs. Here we will review these findings and propose roles that EGFR may play in breast malignancies. In particular, we will discuss the potential roles that EGFR may play in triple-negative tumors, resistance to endocrine therapies, maintenance of stem-like tumor cells, and bone metastasis. Thus, we will propose the contexts in which EGFR may be a therapeutic target.

PMID:
20813200
PMCID:
PMC2991402
DOI:
10.1016/j.semcdb.2010.08.009
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center